

# Chemotherapy agents - Anthracyclines and antibiotics: All Primary cancers

			Daunorubicin		Doxorubicin		Idarubicin		Epirubicin		Mitoxantrone		Actinomycin-D		Bleomycin		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
<b>Both sexes</b>	<b>All cases</b>		<b>23558</b>	<b>3694</b>	<b>15.8</b>	<b>8471</b>	<b>36.3</b>	<b>196</b>	<b>0.8</b>	<b>3</b>	<b>0.0</b>	<b>138</b>	<b>0.6</b>	<b>4084</b>	<b>17.5</b>	<b>1545</b>	<b>6.6</b>
	<b>Age at baseline</b>	<18	5290	1010	19.2	1712	32.5	61	1.2	1	0.0	35	0.7	1071	20.4	56	1.1
		18-19	1964	316	16.2	657	33.8	23	1.2	.	.	7	0.4	411	21.1	47	2.4
		20-24	5470	815	15.0	1890	34.9	47	0.9	2	0.0	24	0.4	1101	20.3	279	5.1
		25-29	5110	810	16.0	1907	37.8	36	0.7	.	.	14	0.3	832	16.4	422	8.3
		30-34	3523	488	14.0	1463	42.1	20	0.6	.	.	29	0.8	427	12.3	438	12.6
		35+	2201	255	11.8	842	38.9	9	0.4	.	.	29	1.3	242	11.2	303	14.0
	<b>Years since diagnosis</b>	5-9	2383	526	22.3	935	39.7	20	0.8	2	0.1	6	0.3	425	18.0	195	8.3
		10-14	7680	1285	16.9	2915	38.3	114	1.5	.	.	45	0.6	1287	16.9	580	7.6
		15-19	7552	1073	14.3	2836	38.0	52	0.7	1	0.0	72	1.0	1283	17.2	420	5.6
		20+	5943	810	13.8	1785	30.4	10	0.2	.	.	15	0.3	1089	18.5	350	5.9
	<b>Age at diagnosis</b>	<1	1778	179	10.1	481	27.3	17	1.0	1	0.1	11	0.6	363	20.6	5	0.3
		1-4	7584	1394	18.5	2316	30.8	61	0.8	1	0.0	35	0.5	1764	23.4	53	0.7
		5-9	5282	791	15.1	1735	33.1	44	0.8	.	.	22	0.4	901	17.2	204	3.9
		10-14	4993	891	18.0	2149	43.5	39	0.8	1	0.0	21	0.4	603	12.2	616	12.5
		15-20	3921	439	11.4	1790	46.5	35	0.9	.	.	49	1.3	453	11.7	667	17.3
<b>Males</b>	<b>All cases</b>		<b>12463</b>	<b>2056</b>	<b>16.7</b>	<b>4563</b>	<b>37.0</b>	<b>108</b>	<b>0.9</b>	<b>1</b>	<b>0.0</b>	<b>76</b>	<b>0.6</b>	<b>2046</b>	<b>16.6</b>	<b>803</b>	<b>6.5</b>
	<b>Age at baseline</b>	<18	2841	568	20.2	947	33.6	26	0.9	.	.	22	0.8	562	19.9	38	1.3
		18-19	1014	181	18.0	350	34.8	14	1.4	.	.	2	0.2	189	18.8	33	3.3
		20-24	2840	424	15.1	998	35.5	26	0.9	1	0.0	10	0.4	519	18.4	154	5.5
		25-29	2800	459	16.6	1037	37.5	26	0.9	.	.	6	0.2	415	15.0	215	7.8
		30-34	1856	268	14.6	796	43.4	11	0.6	.	.	18	1.0	234	12.8	232	12.6
		35+	1112	156	14.2	435	39.7	5	0.5	.	.	18	1.6	127	11.6	131	12.0
	<b>Years since diagnosis</b>	5-9	1326	310	23.6	526	40.2	10	0.8	1	0.1	3	0.2	220	16.8	102	7.8
		10-14	4084	720	17.8	1574	38.9	59	1.5	.	.	23	0.6	665	16.4	302	7.4
		15-19	3918	566	14.6	1499	38.7	32	0.8	.	.	43	1.1	607	15.7	222	5.7
		20+	3135	460	14.8	964	31.1	7	0.2	.	.	7	0.2	554	17.9	177	5.7
	<b>Age at diagnosis</b>	<1	901	85	9.5	248	27.7	7	0.8	.	.	5	0.6	177	19.8	2	0.2
		1-4	3934	766	19.6	1225	31.3	33	0.8	.	.	25	0.6	872	22.3	36	0.9
		5-9	2955	469	16.0	991	33.9	26	0.9	.	.	7	0.2	448	15.3	139	4.7
		10-14	2603	459	17.8	1153	44.7	20	0.8	1	0.0	7	0.3	308	11.9	311	12.1
		15-20	2070	277	13.6	946	46.6	22	1.1	.	.	32	1.6	241	11.8	315	15.5
<b>Females</b>	<b>All cases</b>		<b>11095</b>	<b>1638</b>	<b>14.9</b>	<b>3908</b>	<b>35.6</b>	<b>88</b>	<b>0.8</b>	<b>2</b>	<b>0.0</b>	<b>62</b>	<b>0.6</b>	<b>2038</b>	<b>18.5</b>	<b>742</b>	<b>6.7</b>
	<b>Age at baseline</b>	<18	2449	442	18.1	765	31.4	35	1.4	1	0.0	13	0.5	509	20.9	18	0.7
		18-19	950	135	14.3	307	32.7	9	1.0	.	.	5	0.5	222	23.6	14	1.5
		20-24	2630	391	15.0	892	34.2	21	0.8	1	0.0	14	0.5	582	22.3	125	4.8
		25-29	2310	351	15.3	870	38.1	10	0.4	.	.	8	0.3	417	18.2	207	9.0
		30-34	1667	220	13.3	667	40.6	9	0.5	.	.	11	0.7	193	11.7	206	12.5
		35+	1089	99	9.2	407	38.0	4	0.4	.	.	11	1.0	115	10.7	172	16.1
	<b>Years since diagnosis</b>	5-9	1057	216	20.6	409	39.0	10	1.0	1	0.1	3	0.3	205	19.5	93	8.9
		10-14	3596	565	15.8	1341	37.6	55	1.5	.	.	22	0.6	622	17.4	278	7.8
		15-19	3634	507	14.1	1337	37.2	20	0.6	1	0.0	29	0.8	676	18.8	198	5.5
		20+	2808	350	12.6	821	29.6	3	0.1	.	.	8	0.3	535	19.3	173	6.2
	<b>Age at diagnosis</b>	<1	877	94	10.8	233	26.8	10	1.1	1	0.1	6	0.7	186	21.4	3	0.3
		1-4	3650	628	17.3	1091	30.1	28	0.8	1	0.0	10	0.3	892	24.6	17	0.5
		5-9	2327	322	13.9	744	32.2	18	0.8	.	.	15	0.6	453	19.6	65	2.8
		10-14	2390	432	18.2	996	42.2	19	0.8	.	.	14	0.6	295	12.5	305	12.9
		15-20	1851	162	8.9	844	46.4	13	0.7	.	.	17	0.9	212	11.6	352	19.4

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values  
 Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years  
 If the starting date for a drug was not clearly prior to study entry, they are not included

**Chemotherapy agents - Anthracyclines and antibiotics: All leukemias**

		All cases		Daurubicin		Doxorubicin		Idarubicin		Epirubicin		Mitoxantrone		Actinomycin-D		Bleomycin	
		N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
<b>Both sexes</b>	<b>All cases</b>	<b>7245</b>		<b>3171</b>	<b>44.2</b>	<b>2104</b>	<b>29.3</b>	<b>188</b>	<b>2.6</b>	.	.	<b>105</b>	<b>1.5</b>	<b>64</b>	<b>0.9</b>	<b>2</b>	<b>0.0</b>
	<b>Age at baseline</b>	<18	2096	934	44.9	571	27.4	60	2.9	.	.	35	1.7	13	0.6	.	.
		18-19	769	270	35.4	245	32.1	22	2.9	.	.	7	0.9	5	0.7	.	.
		20-24	1788	700	39.5	520	29.3	44	2.5	.	.	23	1.3	11	0.6	.	.
		25-29	1459	674	46.5	424	29.3	36	2.5	.	.	13	0.9	16	1.1	1	0.1
		30-34	761	380	51.0	227	30.6	19	2.5	.	.	18	2.4	4	0.5	.	.
		35+	372	213	57.9	117	31.8	7	1.9	.	.	9	2.5	15	4.1	1	0.3
	<b>Years since diagnosis</b>	5-9	904	480	53.5	269	30.0	20	2.2	.	.	6	0.7	3	0.3	.	.
		10-14	2445	1091	45.0	725	29.9	113	4.7	.	.	39	1.6	25	1.0	.	.
		15-19	2236	909	41.0	719	32.4	45	2.0	.	.	54	2.4	8	0.4	1	0.0
		20+	1660	691	42.1	391	23.8	10	0.6	.	.	6	0.4	28	1.7	1	0.1
	<b>Age at diagnosis</b>	<1	232	171	75.0	41	17.9	17	7.4	.	.	11	4.8	1	0.4	.	.
		1-4	3421	1288	37.9	911	26.8	57	1.7	.	.	35	1.0	22	0.6	.	.
		5-9	1754	637	36.7	519	29.9	43	2.5	.	.	20	1.2	18	1.0	1	0.1
		10-14	1203	720	60.3	408	34.2	39	3.3	.	.	20	1.7	8	0.7	.	.
		15-20	635	355	57.1	225	36.2	32	5.1	.	.	19	3.1	15	2.4	1	0.2
<b>Males</b>	<b>All cases</b>	<b>3827</b>		<b>1723</b>	<b>45.6</b>	<b>1201</b>	<b>31.7</b>	<b>104</b>	<b>2.7</b>	.	.	<b>55</b>	<b>1.4</b>	<b>43</b>	<b>1.1</b>	<b>1</b>	<b>0.0</b>
	<b>Age at baseline</b>	<18	1136	520	46.3	328	29.1	26	2.3	.	.	22	1.9	10	0.9	.	.
		18-19	411	150	36.8	142	34.7	14	3.4	.	.	2	0.5	4	1.0	.	.
		20-24	891	351	39.8	284	32.1	24	2.7	.	.	10	1.1	7	0.8	.	.
		25-29	783	366	47.3	241	31.1	26	3.4	.	.	5	0.6	11	1.4	.	.
		30-34	397	205	53.1	131	33.9	10	2.6	.	.	11	2.8	3	0.8	.	.
		35+	209	131	63.3	75	36.2	4	1.9	.	.	5	2.4	8	3.9	1	0.5
	<b>Years since diagnosis</b>	5-9	510	275	54.5	164	32.4	10	2.0	.	.	3	0.6	2	0.4	.	.
		10-14	1301	594	46.2	420	32.6	58	4.5	.	.	20	1.5	18	1.4	.	.
		15-19	1136	465	41.4	395	35.2	29	2.6	.	.	30	2.7	3	0.3	1	0.1
		20+	880	389	44.8	222	25.5	7	0.8	.	.	2	0.2	20	2.3	.	.
	<b>Age at diagnosis</b>	<1	110	82	76.6	17	15.9	7	6.5	.	.	5	4.6	.	.	.	.
		1-4	1809	703	39.2	507	28.2	32	1.8	.	.	25	1.4	18	1.0	.	.
		5-9	935	367	39.8	298	32.3	25	2.7	.	.	6	0.6	11	1.2	.	.
		10-14	588	347	59.5	236	40.5	20	3.4	.	.	7	1.2	6	1.0	.	.
		15-20	385	224	59.4	143	37.9	20	5.3	.	.	12	3.2	8	2.1	1	0.3
<b>Females</b>	<b>All cases</b>	<b>3418</b>		<b>1448</b>	<b>42.6</b>	<b>903</b>	<b>26.6</b>	<b>84</b>	<b>2.5</b>	.	.	<b>50</b>	<b>1.5</b>	<b>21</b>	<b>0.6</b>	<b>1</b>	<b>0.0</b>
	<b>Age at baseline</b>	<18	960	414	43.2	243	25.4	34	3.5	.	.	13	1.4	3	0.3	.	.
		18-19	358	120	33.9	103	29.1	8	2.3	.	.	5	1.4	1	0.3	.	.
		20-24	897	349	39.2	236	26.5	20	2.2	.	.	13	1.5	4	0.4	.	.
		25-29	676	308	45.7	183	27.2	10	1.5	.	.	8	1.2	5	0.7	1	0.1
		30-34	364	175	48.7	96	26.9	9	2.5	.	.	7	1.9	1	0.3	.	.
		35+	163	82	50.9	42	26.1	3	1.9	.	.	4	2.5	7	4.3	.	.
	<b>Years since diagnosis</b>	5-9	394	205	52.3	105	26.9	10	2.6	.	.	3	0.8	1	0.3	.	.
		10-14	1144	497	43.8	305	26.8	55	4.8	.	.	19	1.7	7	0.6	.	.
		15-19	1100	444	40.5	324	29.6	16	1.5	.	.	24	2.2	5	0.5	.	.
		20+	780	302	39.1	169	21.9	3	0.4	.	.	4	0.5	8	1.0	1	0.1
	<b>Age at diagnosis</b>	<1	122	89	73.6	24	19.7	10	8.2	.	.	6	4.9	1	0.8	.	.
		1-4	1612	585	36.5	404	25.2	25	1.6	.	.	10	0.6	4	0.2	.	.
		5-9	819	270	33.2	221	27.1	18	2.2	.	.	14	1.7	7	0.9	1	0.1
		10-14	615	373	60.9	172	28.2	19	3.1	.	.	13	2.1	2	0.3	.	.
		15-20	250	131	53.5	82	33.5	12	4.9	.	.	7	2.9	7	2.9	.	.

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values  
 Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years  
 If the starting date for a drug was not clearly prior to study entry, they are not included

		All cases		Daunorubicin		Doxorubicin		Idarubicin		Epirubicin		Mitoxantrone		Actinomycin-D		Bleomycin	
		N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
<b>Both sexes</b>	<b>All cases</b>	<b>6067</b>		<b>2353</b>	<b>39.1</b>	<b>1923</b>	<b>31.9</b>	<b>86</b>	<b>1.4</b>	.	.	<b>22</b>	<b>0.4</b>	<b>59</b>	<b>1.0</b>	<b>2</b>	<b>0.0</b>
	<b>Age at baseline</b>	<18	1812	722	40.1	529	29.3	24	1.3	.	.	6	0.3	12	0.7	.	.
		18-19	666	197	29.8	222	33.6	14	2.1	.	.	2	0.3	4	0.6	.	.
		20-24	1524	508	33.6	479	31.7	23	1.5	.	.	2	0.1	10	0.7	.	.
		25-29	1207	495	41.2	385	32.1	18	1.5	.	.	2	0.2	15	1.2	1	0.1
		30-34	590	272	47.1	202	35.1	7	1.2	.	.	5	0.9	4	0.7	.	.
		35+	268	159	60.0	106	40.0	.	.	.	.	5	1.9	14	5.3	1	0.4
	<b>Years since diagnosis</b>	5-9	777	406	52.6	247	32.0	17	2.2	.	.	4	0.5	3	0.4	.	.
		10-14	2049	802	39.5	668	32.8	44	2.2	.	.	1	0.0	23	1.1	.	.
		15-19	1847	630	34.4	645	35.2	18	1.0	.	.	15	0.8	8	0.4	1	0.1
		20+	1394	515	37.3	363	26.3	7	0.5	.	.	2	0.1	25	1.8	1	0.1
	<b>Age at diagnosis</b>	<1	127	89	71.8	23	18.3	3	2.4	.	.	3	2.4	.	.	.	.
		1-4	3030	995	33.0	853	28.3	31	1.0	.	.	3	0.1	20	0.7	.	.
		5-9	1537	480	31.6	485	31.8	20	1.3	.	.	4	0.3	17	1.1	1	0.1
		10-14	940	538	57.4	373	39.9	23	2.5	.	.	8	0.9	8	0.9	.	.
		15-20	433	251	59.6	189	44.9	9	2.1	.	.	4	0.9	14	3.3	1	0.2
<b>Males</b>	<b>All cases</b>	<b>3231</b>		<b>1303</b>	<b>40.7</b>	<b>1101</b>	<b>34.4</b>	<b>53</b>	<b>1.7</b>	.	.	<b>12</b>	<b>0.4</b>	<b>41</b>	<b>1.3</b>	<b>1</b>	<b>0.0</b>
	<b>Age at baseline</b>	<18	982	406	41.7	303	31.0	10	1.0	.	.	3	0.3	10	1.0	.	.
		18-19	359	112	31.5	131	36.7	10	2.8	.	.	.	.	4	1.1	.	.
		20-24	759	252	33.5	260	34.5	13	1.7	.	.	2	0.3	6	0.8	.	.
		25-29	660	281	42.8	225	34.3	16	2.4	.	.	1	0.2	11	1.7	.	.
		30-34	313	151	49.7	114	37.5	4	1.3	.	.	3	1.0	3	1.0	.	.
		35+	158	101	64.3	68	43.3	.	.	.	.	3	1.9	7	4.5	1	0.6
	<b>Years since diagnosis</b>	5-9	440	232	53.2	147	33.7	8	1.8	.	.	1	0.2	2	0.5	.	.
		10-14	1099	450	41.3	384	35.2	26	2.4	.	.	1	0.1	18	1.6	.	.
		15-19	949	329	35.1	362	38.6	14	1.5	.	.	9	1.0	3	0.3	1	0.1
		20+	743	292	39.6	208	28.2	5	0.7	.	.	1	0.1	18	2.4	.	.
	<b>Age at diagnosis</b>	<1	63	47	77.0	10	16.1	2	3.2	.	.	1	1.6	.	.	.	.
		1-4	1591	537	33.9	476	30.1	19	1.2	.	.	3	0.2	17	1.1	.	.
		5-9	829	288	35.2	280	34.1	14	1.7	.	.	2	0.2	11	1.3	.	.
		10-14	476	270	56.8	217	45.7	10	2.1	.	.	3	0.6	6	1.3	.	.
		15-20	272	161	61.0	118	44.7	8	3.0	.	.	3	1.1	7	2.6	1	0.4
<b>Females</b>	<b>All cases</b>	<b>2836</b>		<b>1050</b>	<b>37.3</b>	<b>822</b>	<b>29.2</b>	<b>33</b>	<b>1.2</b>	.	.	<b>10</b>	<b>0.4</b>	<b>18</b>	<b>0.6</b>	<b>1</b>	<b>0.0</b>
	<b>Age at baseline</b>	<18	830	316	38.2	226	27.3	14	1.7	.	.	3	0.4	2	0.2	.	.
		18-19	307	85	28.0	91	29.9	4	1.3	.	.	2	0.7	.	.	.	.
		20-24	765	256	33.7	219	28.9	10	1.3	.	.	.	.	4	0.5	.	.
		25-29	547	214	39.3	160	29.4	2	0.4	.	.	1	0.2	4	0.7	1	0.2
		30-34	277	121	44.2	88	32.4	3	1.1	.	.	2	0.7	1	0.4	.	.
		35+	110	58	53.7	38	35.2	.	.	.	.	2	1.9	7	6.5	.	.
	<b>Years since diagnosis</b>	5-9	337	174	51.8	100	29.9	9	2.7	.	.	3	0.9	1	0.3	.	.
		10-14	950	352	37.3	284	30.1	18	1.9	.	.	.	.	5	0.5	.	.
		15-19	898	301	33.7	283	31.7	4	0.4	.	.	6	0.7	5	0.6	.	.
		20+	651	223	34.6	155	24.1	2	0.3	.	.	1	0.2	7	1.1	1	0.2
	<b>Age at diagnosis</b>	<1	64	42	66.7	13	20.3	1	1.6	.	.	2	3.1	.	.	.	.
		1-4	1439	458	32.0	377	26.4	12	0.8	.	.	.	.	3	0.2	.	.
		5-9	708	192	27.3	205	29.2	6	0.9	.	.	2	0.3	6	0.9	1	0.1
		10-14	464	268	57.9	156	33.8	13	2.8	.	.	5	1.1	2	0.4	.	.
		15-20	161	90	57.3	71	45.2	1	0.6	.	.	1	0.6	7	4.5	.	.

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values  
 Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years  
 If the starting date for a drug was not clearly prior to study entry, they are not included

			Daunorubicin		Doxorubicin		Idarubicin		Epirubicin		Mitoxantrone		Actinomycin-D		Bleomycin		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
<b>Both sexes</b>	<b>All cases</b>		<b>871</b>	<b>710</b>	<b>82.7</b>	<b>125</b>	<b>14.5</b>	<b>97</b>	<b>11.2</b>	.	.	<b>76</b>	<b>8.8</b>	<b>4</b>	<b>0.5</b>	.	.
	<b>Age at baseline</b>	<18	225	191	86.4	27	12.1	36	16.1	.	.	28	12.5	1	0.4	.	.
		18-19	82	63	77.8	19	23.5	8	9.9	.	.	5	6.2	1	1.2	.	.
		20-24	191	162	85.7	24	12.7	19	10.0	.	.	19	10.0	1	0.5	.	.
		25-29	186	160	87.0	32	17.3	17	9.2	.	.	10	5.4	.	.	.	.
		30-34	118	89	76.7	17	14.7	11	9.5	.	.	11	9.5	.	.	.	.
		35+	69	45	66.2	6	8.8	6	8.8	.	.	3	4.5	1	1.5	.	.
	<b>Years since diagnosis</b>	5-9	81	66	83.5	14	17.5	3	3.8	.	.	2	2.5	.	.	.	.
		10-14	307	262	86.2	40	13.1	68	22.3	.	.	34	11.1	2	0.7	.	.
		15-19	301	237	79.3	55	18.4	24	8.0	.	.	37	12.3	.	.	.	.
		20+	182	145	81.9	16	8.9	2	1.1	.	.	3	1.7	2	1.1	.	.
	<b>Age at diagnosis</b>	<1	90	74	83.1	15	16.9	14	15.7	.	.	8	9.0	1	1.1	.	.
		1-4	299	253	86.3	38	12.8	26	8.7	.	.	31	10.4	2	0.7	.	.
		5-9	163	138	85.2	20	12.4	21	13.0	.	.	14	8.6	.	.	.	.
		10-14	182	155	87.1	26	14.6	15	8.4	.	.	11	6.2	.	.	.	.
		15-20	137	90	65.7	26	19.0	21	15.3	.	.	12	8.8	1	0.7	.	.
<b>Males</b>	<b>All cases</b>		<b>427</b>	<b>350</b>	<b>83.7</b>	<b>61</b>	<b>14.5</b>	<b>46</b>	<b>10.9</b>	.	.	<b>40</b>	<b>9.5</b>	<b>2</b>	<b>0.5</b>	.	.
	<b>Age at baseline</b>	<18	122	101	85.6	15	12.4	16	13.2	.	.	19	15.7	.	.	.	.
		18-19	42	32	76.2	8	19.0	4	9.5	.	.	2	4.8	.	.	.	.
		20-24	92	79	86.8	14	15.4	9	9.8	.	.	7	7.6	1	1.1	.	.
		25-29	82	73	91.3	12	14.8	9	11.1	.	.	4	5.0	.	.	.	.
		30-34	56	42	76.4	10	18.2	5	9.1	.	.	6	10.9	.	.	.	.
		35+	33	23	71.9	2	6.3	3	9.4	.	.	2	6.3	1	3.1	.	.
	<b>Years since diagnosis</b>	5-9	47	37	80.4	11	23.4	2	4.3	.	.	2	4.3	.	.	.	.
		10-14	152	131	87.9	23	15.3	31	20.7	.	.	18	12.0	.	.	.	.
		15-19	141	109	77.9	22	15.7	12	8.5	.	.	19	13.5	.	.	.	.
		20+	87	73	88.0	5	5.9	1	1.2	.	.	1	1.2	2	2.4	.	.
	<b>Age at diagnosis</b>	<1	39	31	81.6	6	15.8	5	13.2	.	.	4	10.5	.	.	.	.
		1-4	165	139	86.9	19	11.5	13	7.9	.	.	22	13.4	1	0.6	.	.
		5-9	75	65	87.8	8	11.0	9	12.2	.	.	3	4.1	.	.	.	.
		10-14	74	63	87.5	11	15.3	9	12.5	.	.	4	5.6	.	.	.	.
		15-20	74	52	70.3	17	23.0	10	13.5	.	.	7	9.5	1	1.4	.	.
<b>Females</b>	<b>All cases</b>		<b>444</b>	<b>360</b>	<b>81.6</b>	<b>64</b>	<b>14.5</b>	<b>51</b>	<b>11.6</b>	.	.	<b>36</b>	<b>8.2</b>	<b>2</b>	<b>0.5</b>	.	.
	<b>Age at baseline</b>	<18	103	90	87.4	12	11.7	20	19.4	.	.	9	8.7	1	1.0	.	.
		18-19	40	31	79.5	11	28.2	4	10.3	.	.	3	7.7	1	2.6	.	.
		20-24	99	83	84.7	10	10.2	10	10.2	.	.	12	12.2	.	.	.	.
		25-29	104	87	83.7	20	19.2	8	7.7	.	.	6	5.8	.	.	.	.
		30-34	62	47	77.0	7	11.5	6	9.8	.	.	5	8.2	.	.	.	.
		35+	36	22	61.1	4	11.1	3	8.3	.	.	1	2.9	.	.	.	.
	<b>Years since diagnosis</b>	5-9	34	29	87.9	3	9.1	1	3.0	.	.	.	.	.	.	.	.
		10-14	155	131	84.5	17	11.0	37	23.9	.	.	16	10.3	2	1.3	.	.
		15-19	160	128	80.5	33	20.8	12	7.5	.	.	18	11.3	.	.	.	.
		20+	95	72	76.6	11	11.7	1	1.1	.	.	2	2.2	.	.	.	.
	<b>Age at diagnosis</b>	<1	51	43	84.3	9	17.6	9	17.6	.	.	4	7.8	1	2.0	.	.
		1-4	134	114	85.7	19	14.3	13	9.8	.	.	9	6.8	1	0.8	.	.
		5-9	88	73	83.0	12	13.6	12	13.6	.	.	11	12.5	.	.	.	.
		10-14	108	92	86.8	15	14.2	6	5.7	.	.	7	6.6	.	.	.	.
		15-20	63	38	60.3	9	14.3	11	17.5	.	.	5	8.1	.	.	.	.

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values  
 Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years  
 If the starting date for a drug was not clearly prior to study entry, they are not included

**Chemotherapy agents - Anthracyclines and antibiotics: All CNS**

		All cases		Daurorubicin		Doxorubicin		Idarubicin		Epirubicin		Mitoxantrone		Actinomycin-D		Bleomycin	
		All cases		N	%	N	%	N	%	N	%	N	%	N	%	N	%
<b>Both sexes</b>	<b>All cases</b>	<b>4184</b>		<b>2</b>	<b>0.0</b>	<b>33</b>	<b>0.8</b>	<b>3</b>	<b>0.1</b>	.	.	.	.	<b>77</b>	<b>1.9</b>	<b>8</b>	<b>0.2</b>
	<b>Age at baseline</b>	<18	891	.	.	4	0.5	.	.	.	.	.	.	27	3.1	2	0.2
		18-19	349	1	0.3	.	.	1	0.3	.	.	.	.	8	2.4	1	0.3
		20-24	1093	1	0.1	11	1.0	2	0.2	.	.	.	.	19	1.8	3	0.3
		25-29	1021	.	.	9	0.9	.	.	.	.	.	.	15	1.5	2	0.2
		30-34	581	.	.	8	1.4	.	.	.	.	.	.	7	1.2	.	.
		35+	249	.	.	1	0.4	.	.	.	.	.	.	1	0.4	.	.
	<b>Years since diagnosis</b>	5-9	428	1	0.2	4	1.0	.	.	.	.	.	.	11	2.6	3	0.7
		10-14	1424	1	0.1	8	0.6	.	.	.	.	.	.	26	1.8	3	0.2
		15-19	1325	.	.	16	1.2	3	0.2	.	.	.	.	21	1.6	1	0.1
		20+	1007	.	.	5	0.5	.	.	.	.	.	.	19	1.9	1	0.1
	<b>Age at diagnosis</b>	<1	205	.	.	1	0.5	.	.	.	.	.	.	13	6.4	2	1.0
		1-4	1223	.	.	5	0.4	2	0.2	.	.	.	.	37	3.1	.	.
		5-9	1326	1	0.1	12	0.9	1	0.1	.	.	.	.	13	1.0	1	0.1
		10-14	996	1	0.1	9	0.9	.	.	.	.	.	.	11	1.1	5	0.5
		15-20	434	.	.	6	1.4	.	.	.	.	.	.	3	0.7	.	.
<b>Males</b>	<b>All cases</b>	<b>2276</b>		<b>2</b>	<b>0.1</b>	<b>19</b>	<b>0.8</b>	<b>1</b>	<b>0.0</b>	.	.	.	.	<b>45</b>	<b>2.0</b>	<b>6</b>	<b>0.3</b>
	<b>Age at baseline</b>	<18	494	.	.	3	0.6	.	.	.	.	.	.	15	3.1	1	0.2
		18-19	176	1	0.6	.	.	.	.	.	.	.	.	5	2.9	1	0.6
		20-24	584	1	0.2	7	1.2	1	0.2	.	.	.	.	10	1.7	2	0.3
		25-29	579	.	.	5	0.9	.	.	.	.	.	.	11	1.9	2	0.3
		30-34	309	.	.	4	1.3	.	.	.	.	.	.	4	1.3	.	.
		35+	134	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	<b>Years since diagnosis</b>	5-9	242	1	0.4	2	0.8	.	.	.	.	.	.	7	3.0	2	0.8
		10-14	766	1	0.1	6	0.8	.	.	.	.	.	.	14	1.9	2	0.3
		15-19	720	.	.	9	1.3	1	0.1	.	.	.	.	10	1.4	1	0.1
		20+	548	.	.	2	0.4	.	.	.	.	.	.	14	2.6	1	0.2
	<b>Age at diagnosis</b>	<1	121	.	.	1	0.8	.	.	.	.	.	.	8	6.7	1	0.8
		1-4	647	.	.	1	0.2	.	.	.	.	.	.	20	3.1	.	.
		5-9	738	1	0.1	9	1.2	1	0.1	.	.	.	.	9	1.2	1	0.1
		10-14	526	1	0.2	5	1.0	.	.	.	.	.	.	6	1.2	4	0.8
		15-20	244	.	.	3	1.3	.	.	.	.	.	.	2	0.9	.	.
<b>Females</b>	<b>All cases</b>	<b>1908</b>		.	.	<b>14</b>	<b>0.7</b>	<b>2</b>	<b>0.1</b>	.	.	.	.	<b>32</b>	<b>1.7</b>	<b>2</b>	<b>0.1</b>
	<b>Age at baseline</b>	<18	397	.	.	1	0.3	.	.	.	.	.	.	12	3.0	1	0.3
		18-19	173	.	.	.	.	1	0.6	.	.	.	.	3	1.8	.	.
		20-24	509	.	.	4	0.8	1	0.2	.	.	.	.	9	1.8	1	0.2
		25-29	442	.	.	4	0.9	.	.	.	.	.	.	4	0.9	.	.
		30-34	272	.	.	4	1.5	.	.	.	.	.	.	3	1.1	.	.
		35+	115	.	.	1	0.9	.	.	.	.	.	.	1	0.9	.	.
	<b>Years since diagnosis</b>	5-9	186	.	.	2	1.1	.	.	.	.	.	.	4	2.2	1	0.5
		10-14	658	.	.	2	0.3	.	.	.	.	.	.	12	1.8	1	0.2
		15-19	605	.	.	7	1.2	2	0.3	.	.	.	.	11	1.8	.	.
		20+	459	.	.	3	0.7	.	.	.	.	.	.	5	1.1	.	.
	<b>Age at diagnosis</b>	<1	84	.	.	.	.	.	.	.	.	.	.	5	6.0	1	1.2
		1-4	576	.	.	4	0.7	2	0.4	.	.	.	.	17	3.0	.	.
		5-9	588	.	.	3	0.5	.	.	.	.	.	.	4	0.7	.	.
		10-14	470	.	.	4	0.9	.	.	.	.	.	.	5	1.1	1	0.2
		15-20	190	.	.	3	1.6	.	.	.	.	.	.	1	0.5	.	.

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values  
 Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years  
 If the starting date for a drug was not clearly prior to study entry, they are not included

			D Daunorubicin		D Doxorubicin		D Idarubicin		D Epirubicin		D Mitoxantrone		D Actinomycin-D		D Bleomycin			
			All cases		N	%	N	%	N	%	N	%	N	%	N	%		
<b>Both sexes</b>	<b>All cases</b>		<b>2509</b>		<b>1</b>	<b>0.0</b>	<b>5</b>	<b>0.2</b>	<b>2</b>	<b>0.1</b>	.	.	.	.	<b>57</b>	<b>2.3</b>	<b>3</b>	<b>0.1</b>
	<b>Age at baseline</b>	<18	493	.	.	.	.	.	.	.	.	.	.	.	25	5.1	2	0.4
		18-19	202	.	.	.	.	.	.	.	.	.	.	.	8	4.1	.	.
		20-24	662	1	0.2	5	0.8	2	0.3	.	.	.	.	13	2.0	1	0.2	
		25-29	629	.	.	.	.	.	.	.	.	.	.	10	1.6	.	.	
		30-34	357	.	.	.	.	.	.	.	.	.	.	1	0.3	.	.	
		35+	166	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	<b>Years since diagnosis</b>	5-9	219	.	.	2	0.9	.	.	.	.	.	.	9	4.2	.	.	
		10-14	838	1	0.1	2	0.2	.	.	.	.	.	.	21	2.5	2	0.2	
		15-19	778	.	.	1	0.1	2	0.3	.	.	.	.	12	1.6	.	.	
		20+	674	.	.	.	.	.	.	.	.	.	.	15	2.2	1	0.1	
	<b>Age at diagnosis</b>	<1	144	.	.	.	.	.	.	.	.	.	.	12	8.4	2	1.4	
		1-4	741	.	.	.	.	1	0.1	.	.	.	.	35	4.8	.	.	
		5-9	750	1	0.1	2	0.3	1	0.1	.	.	.	.	7	0.9	1	0.1	
		10-14	599	.	.	1	0.2	.	.	.	.	.	.	2	0.3	.	.	
		15-20	275	.	.	2	0.7	.	.	.	.	.	.	1	0.4	.	.	
<b>Males</b>	<b>All cases</b>		<b>1302</b>		<b>1</b>	<b>0.1</b>	<b>3</b>	<b>0.2</b>	<b>1</b>	<b>0.1</b>	.	.	.	.	<b>32</b>	<b>2.5</b>	<b>2</b>	<b>0.2</b>
	<b>Age at baseline</b>	<18	258	.	.	.	.	.	.	.	.	.	.	13	5.1	1	0.4	
		18-19	102	.	.	.	.	.	.	.	.	.	.	5	5.1	.	.	
		20-24	325	1	0.3	3	0.9	1	0.3	.	.	.	.	6	1.9	1	0.3	
		25-29	351	.	.	.	.	.	.	.	.	.	.	8	2.3	.	.	
		30-34	178	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
		35+	88	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	<b>Years since diagnosis</b>	5-9	117	.	.	.	.	.	.	.	.	.	.	6	5.1	.	.	
		10-14	437	1	0.2	2	0.5	.	.	.	.	.	.	9	2.1	1	0.2	
		15-19	391	.	.	1	0.3	1	0.3	.	.	.	.	6	1.6	.	.	
		20+	357	.	.	.	.	.	.	.	.	.	.	11	3.1	1	0.3	
	<b>Age at diagnosis</b>	<1	81	.	.	.	.	.	.	.	.	.	.	7	8.6	1	1.2	
		1-4	373	.	.	.	.	.	.	.	.	.	.	19	5.1	.	.	
		5-9	394	1	0.3	2	0.5	1	0.3	.	.	.	.	5	1.3	1	0.3	
		10-14	302	.	.	1	0.3	.	.	.	.	.	.	.	.	.	.	
		15-20	152	.	.	.	.	.	.	.	.	.	.	1	0.7	.	.	
<b>Females</b>	<b>All cases</b>		<b>1207</b>	.	.	<b>2</b>	<b>0.2</b>	<b>1</b>	<b>0.1</b>	.	.	.	.	<b>25</b>	<b>2.1</b>	<b>1</b>	<b>0.1</b>	
	<b>Age at baseline</b>	<18	235	.	.	.	.	.	.	.	.	.	.	12	5.1	1	0.4	
		18-19	100	.	.	.	.	.	.	.	.	.	.	3	3.1	.	.	
		20-24	337	.	.	2	0.6	1	0.3	.	.	.	.	7	2.1	.	.	
		25-29	278	.	.	.	.	.	.	.	.	.	.	2	0.7	.	.	
		30-34	179	.	.	.	.	.	.	.	.	.	.	1	0.6	.	.	
		35+	78	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	<b>Years since diagnosis</b>	5-9	102	.	.	2	2.0	.	.	.	.	.	.	3	3.0	.	.	
		10-14	401	.	.	.	.	.	.	.	.	.	.	12	3.0	1	0.3	
		15-19	387	.	.	.	.	1	0.3	.	.	.	.	6	1.6	.	.	
		20+	317	.	.	.	.	.	.	.	.	.	.	4	1.3	.	.	
	<b>Age at diagnosis</b>	<1	63	.	.	.	.	.	.	.	.	.	.	5	8.1	1	1.6	
		1-4	368	.	.	.	.	1	0.3	.	.	.	.	16	4.4	.	.	
		5-9	356	.	.	.	.	.	.	.	.	.	.	2	0.6	.	.	
		10-14	297	.	.	.	.	.	.	.	.	.	.	2	0.7	.	.	
		15-20	123	.	.	2	1.7	.	.	.	.	.	.	.	.	.	.	

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values  
 Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years  
 If the starting date for a drug was not clearly prior to study entry, they are not included

			Daunorubicin		Doxorubicin		Idarubicin		Epirubicin		Mitoxantrone		Actinomycin-D		Bleomycin		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
<b>Both sexes</b>	<b>All cases</b>		<b>979</b>	<b>1</b>	<b>0.1</b>	<b>24</b>	<b>2.5</b>	.	.	.	.	.	.	<b>16</b>	<b>1.7</b>	<b>1</b>	<b>0.1</b>
	<b>Age at baseline</b>	<18	233	.	.	2	0.9	.	.	.	.	.	.	1	0.4	.	.
		18-19	77	1	1.4	.	.	.	.	.	.	.	.	.	.	1	1.4
		20-24	273	.	.	5	1.9	.	.	.	.	.	.	5	1.9	.	.
		25-29	236	.	.	8	3.4	.	.	.	.	.	.	3	1.3	.	.
		30-34	126	.	.	8	6.4	.	.	.	.	.	.	6	4.8	.	.
		35+	34	.	.	1	3.1	.	.	.	.	.	.	1	3.1	.	.
	<b>Years since diagnosis</b>	5-9	119	1	0.9	1	0.9	.	.	.	.	.	.	1	0.9	1	0.9
		10-14	333	.	.	5	1.5	.	.	.	.	.	.	3	0.9	.	.
		15-19	323	.	.	13	4.1	.	.	.	.	.	.	8	2.5	.	.
		20+	204	.	.	5	2.5	.	.	.	.	.	.	4	2.0	.	.
	<b>Age at diagnosis</b>	<1	23	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		1-4	279	.	.	4	1.5	.	.	.	.	.	.	2	0.7	.	.
		5-9	402	.	.	9	2.3	.	.	.	.	.	.	6	1.5	.	.
		10-14	217	1	0.5	7	3.3	.	.	.	.	.	.	6	2.8	1	0.5
		15-20	58	.	.	4	7.3	.	.	.	.	.	.	2	3.6	.	.
<b>Males</b>	<b>All cases</b>		<b>599</b>	<b>1</b>	<b>0.2</b>	<b>13</b>	<b>2.2</b>	.	.	.	.	.	.	<b>10</b>	<b>1.7</b>	<b>1</b>	<b>0.2</b>
	<b>Age at baseline</b>	<18	141	.	.	1	0.7	.	.	.	.	.	.	1	0.7	.	.
		18-19	43	1	2.4	.	.	.	.	.	.	.	.	.	.	1	2.4
		20-24	177	.	.	4	2.3	.	.	.	.	.	.	4	2.3	.	.
		25-29	145	.	.	4	2.8	.	.	.	.	.	.	1	0.7	.	.
		30-34	71	.	.	4	5.7	.	.	.	.	.	.	4	5.7	.	.
		35+	22	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	<b>Years since diagnosis</b>	5-9	72	1	1.5	1	1.5	.	.	.	.	.	.	1	1.5	1	1.5
		10-14	196	.	.	3	1.5	.	.	.	.	.	.	3	1.5	.	.
		15-19	207	.	.	7	3.4	.	.	.	.	.	.	3	1.5	.	.
		20+	124	.	.	2	1.7	.	.	.	.	.	.	3	2.5	.	.
	<b>Age at diagnosis</b>	<1	16	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		1-4	168	.	.	1	0.6	.	.	.	.	.	.	1	0.6	.	.
		5-9	257	.	.	6	2.4	.	.	.	.	.	.	4	1.6	.	.
		10-14	123	1	0.8	3	2.5	.	.	.	.	.	.	4	3.3	1	0.8
		15-20	35	.	.	3	9.4	.	.	.	.	.	.	1	3.1	.	.
<b>Females</b>	<b>All cases</b>		<b>380</b>	.	.	<b>11</b>	<b>2.9</b>	.	.	.	.	.	.	<b>6</b>	<b>1.6</b>	.	.
	<b>Age at baseline</b>	<18	92	.	.	1	1.1	.	.	.	.	.	.	.	.	.	.
		18-19	34	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		20-24	96	.	.	1	1.1	.	.	.	.	.	.	1	1.1	.	.
		25-29	91	.	.	4	4.4	.	.	.	.	.	.	2	2.2	.	.
		30-34	55	.	.	4	7.3	.	.	.	.	.	.	2	3.6	.	.
		35+	12	.	.	1	8.3	.	.	.	.	.	.	1	8.3	.	.
	<b>Years since diagnosis</b>	5-9	47	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		10-14	137	.	.	2	1.5	.	.	.	.	.	.	.	.	.	.
		15-19	116	.	.	6	5.3	.	.	.	.	.	.	5	4.4	.	.
		20+	80	.	.	3	3.8	.	.	.	.	.	.	1	1.3	.	.
	<b>Age at diagnosis</b>	<1	7	.	.	.	.	.	.	.	.	.	.	.	.	.	.
		1-4	111	.	.	3	2.7	.	.	.	.	.	.	1	0.9	.	.
		5-9	145	.	.	3	2.1	.	.	.	.	.	.	2	1.4	.	.
		10-14	94	.	.	4	4.3	.	.	.	.	.	.	2	2.2	.	.
		15-20	23	.	.	1	4.3	.	.	.	.	.	.	1	4.3	.	.

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values  
 Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years  
 If the starting date for a drug was not clearly prior to study entry, they are not included

# Chemotherapy agents - Anthracyclines and antibiotics: Hodgkin

			Daunorubicin		Doxorubicin		Idarubicin		Epirubicin		Mitoxantrone		Actinomycin-D		Bleomycin		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
<b>Both sexes</b>	<b>All cases</b>		<b>2827</b>	<b>6</b>	<b>0.2</b>	<b>1333</b>	<b>47.9</b>	<b>1</b>	<b>0.0</b>	<b>.</b>	<b>.</b>	<b>27</b>	<b>1.0</b>	<b>3</b>	<b>0.1</b>	<b>1069</b>	<b>38.4</b>
	<b>Age at baseline</b>	<18	55	.	.	35	64.8	.	.	.	.	.	.	1	1.8	28	51.9
		18-19	55	.	.	33	60.0	.	.	.	.	.	.	.	.	26	47.3
		20-24	328	1	0.3	195	60.6	.	.	.	.	.	.	.	.	170	52.8
		25-29	733	2	0.3	402	55.5	.	.	.	.	.	.	.	.	313	43.2
		30-34	862	2	0.2	418	49.4	.	.	.	.	9	1.1	.	.	322	38.1
		35+	794	1	0.1	250	32.0	1	0.1	.	.	18	2.3	2	0.3	210	26.9
	<b>Years since diagnosis</b>	5-9	221	1	0.5	126	58.1	.	.	.	.	.	.	1	0.5	113	52.1
		10-14	867	2	0.2	489	57.2	.	.	.	.	4	0.5	.	.	407	47.5
		15-19	930	2	0.2	425	46.6	1	0.1	.	.	15	1.6	.	.	309	33.9
		20+	809	1	0.1	293	36.7	.	.	.	.	8	1.0	2	0.3	240	30.1
	<b>Age at diagnosis</b>	1-4	71	.	.	32	45.7	.	.	.	.	.	.	.	.	23	32.9
		5-9	353	1	0.3	183	52.3	.	.	.	.	.	.	2	0.6	148	42.3
		10-14	1026	2	0.2	557	55.0	.	.	.	.	.	.	.	.	428	42.3
		15-20	1377	3	0.2	561	41.6	1	0.1	.	.	27	2.0	1	0.1	470	34.8
<b>Males</b>	<b>All cases</b>		<b>1458</b>	<b>3</b>	<b>0.2</b>	<b>683</b>	<b>47.5</b>	<b>.</b>	<b>.</b>	<b>.</b>	<b>.</b>	<b>17</b>	<b>1.2</b>	<b>2</b>	<b>0.1</b>	<b>551</b>	<b>38.3</b>
	<b>Age at baseline</b>	<18	42	.	.	28	68.3	.	.	.	.	.	.	1	2.4	22	53.7
		18-19	44	.	.	26	59.1	.	.	.	.	.	.	.	.	21	47.7
		20-24	207	1	0.5	120	59.4	.	.	.	.	.	.	.	.	106	52.5
		25-29	401	1	0.3	201	50.9	.	.	.	.	.	.	.	.	156	39.4
		30-34	429	1	0.2	213	50.1	.	.	.	.	6	1.4	.	.	163	38.4
		35+	335	.	.	95	28.7	.	.	.	.	11	3.3	1	0.3	83	25.2
	<b>Years since diagnosis</b>	5-9	126	1	0.8	69	56.1	.	.	.	.	.	.	1	0.8	64	52.0
		10-14	441	.	.	244	56.1	.	.	.	.	2	0.5	.	.	203	46.6
		15-19	492	2	0.4	225	46.5	.	.	.	.	11	2.3	.	.	160	33.1
		20+	399	.	.	145	36.6	.	.	.	.	4	1.0	1	0.3	124	31.4
	<b>Age at diagnosis</b>	1-4	52	.	.	24	47.1	.	.	.	.	.	.	.	.	16	31.4
		5-9	259	1	0.4	133	52.0	.	.	.	.	.	.	2	0.8	110	43.0
		10-14	522	1	0.2	287	55.6	.	.	.	.	.	.	.	.	224	43.4
		15-20	625	1	0.2	239	38.9	.	.	.	.	17	2.8	.	.	201	32.7
<b>Females</b>	<b>All cases</b>		<b>1369</b>	<b>3</b>	<b>0.2</b>	<b>650</b>	<b>48.3</b>	<b>1</b>	<b>0.1</b>	<b>.</b>	<b>.</b>	<b>10</b>	<b>0.7</b>	<b>1</b>	<b>0.1</b>	<b>518</b>	<b>38.5</b>
	<b>Age at baseline</b>	<18	13	.	.	7	53.8	.	.	.	.	.	.	.	.	6	46.2
		18-19	11	.	.	7	63.6	.	.	.	.	.	.	.	.	5	45.5
		20-24	121	.	.	75	62.5	.	.	.	.	.	.	.	.	64	53.3
		25-29	332	1	0.3	201	61.1	.	.	.	.	.	.	.	.	157	47.7
		30-34	433	1	0.2	205	48.7	.	.	.	.	3	0.7	.	.	159	37.8
		35+	459	1	0.2	155	34.4	1	0.2	.	.	7	1.5	1	0.2	127	28.2
	<b>Years since diagnosis</b>	5-9	95	.	.	57	60.6	.	.	.	.	.	.	.	.	49	52.1
		10-14	426	2	0.5	245	58.3	.	.	.	.	2	0.5	.	.	204	48.6
		15-19	438	.	.	200	46.7	1	0.2	.	.	4	0.9	.	.	149	34.8
		20+	410	1	0.2	148	36.7	.	.	.	.	4	1.0	1	0.2	116	28.8
	<b>Age at diagnosis</b>	1-4	19	.	.	8	42.1	.	.	.	.	.	.	.	.	7	36.8
		5-9	94	.	.	50	53.2	.	.	.	.	.	.	.	.	38	40.4
		10-14	504	1	0.2	270	54.3	.	.	.	.	.	.	.	.	204	41.0
		15-20	752	2	0.3	322	43.8	1	0.1	.	.	10	1.4	1	0.1	269	36.6

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values  
 Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years  
 If the starting date for a drug was not clearly prior to study entry, they are not included



			Daunorubicin		Doxorubicin		Idarubicin		Epirubicin		Mitoxantrone		Actinomycin-D		Bleomycin		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
<b>Both sexes</b>	<b>All cases</b>		<b>1915</b>	<b>493</b>	<b>26.0</b>	<b>1001</b>	<b>52.7</b>	<b>4</b>	<b>0.2</b>	<b>.</b>	<b>.</b>	<b>4</b>	<b>0.2</b>	<b>19</b>	<b>1.0</b>	<b>71</b>	<b>3.7</b>
	<b>Age at baseline</b>	<18	200	70	35.4	92	46.2	1	0.5	.	.	.	.	.	.	6	3.0
		18-19	119	43	36.4	57	48.3	.	.	.	.	.	.	1	0.8	2	1.7
		20-24	405	108	26.7	226	55.9	1	0.2	.	.	.	.	1	0.2	8	2.0
		25-29	526	129	24.9	283	54.5	.	.	.	.	.	.	7	1.3	13	2.5
		30-34	438	105	24.0	230	52.6	1	0.2	.	.	2	0.5	7	1.6	26	5.9
		35+	227	38	17.0	113	50.7	1	0.4	.	.	2	0.9	3	1.3	16	7.2
	<b>Years since diagnosis</b>	5-9	132	41	31.1	65	49.6	.	.	.	.	.	.	1	0.8	7	5.3
		10-14	609	184	30.5	341	56.4	1	0.2	.	.	1	0.2	5	0.8	22	3.6
		15-19	657	157	24.1	355	54.4	3	0.5	.	.	3	0.5	8	1.2	20	3.1
		20+	517	111	21.8	240	46.9	.	.	.	.	.	.	5	1.0	22	4.3
	<b>Age at diagnosis</b>	<1	12	4	33.3	4	33.3	.	.	.	.	.	.	.	.	.	.
		1-4	315	100	32.3	155	49.7	2	0.6	.	.	.	.	.	.	7	2.2
		5-9	579	146	25.4	292	50.7	.	.	.	.	.	.	3	0.5	13	2.3
		10-14	602	165	27.5	309	51.6	.	.	.	.	1	0.2	6	1.0	16	2.7
		15-20	407	78	19.4	241	60.1	2	0.5	.	.	3	0.7	10	2.5	35	8.8
<b>Males</b>	<b>All cases</b>		<b>1290</b>	<b>315</b>	<b>24.6</b>	<b>663</b>	<b>51.8</b>	<b>3</b>	<b>0.2</b>	<b>.</b>	<b>.</b>	<b>3</b>	<b>0.2</b>	<b>14</b>	<b>1.1</b>	<b>43</b>	<b>3.4</b>
	<b>Age at baseline</b>	<18	138	44	32.4	64	46.7	.	.	.	.	.	.	.	.	4	2.9
		18-19	87	29	33.7	42	48.8	.	.	.	.	.	.	1	1.2	2	2.3
		20-24	264	68	25.8	146	55.3	1	0.4	.	.	.	.	.	.	5	1.9
		25-29	367	89	24.5	194	53.4	.	.	.	.	.	.	5	1.4	7	1.9
		30-34	286	61	21.4	150	52.6	1	0.4	.	.	1	0.4	6	2.1	18	6.3
		35+	148	24	16.4	67	45.9	1	0.7	.	.	2	1.4	2	1.4	7	4.8
	<b>Years since diagnosis</b>	5-9	99	30	30.3	49	50.0	.	.	.	.	.	.	.	.	4	4.0
		10-14	413	121	29.5	223	54.3	1	0.2	.	.	1	0.2	4	1.0	15	3.6
		15-19	426	96	22.6	230	54.2	2	0.5	.	.	2	0.5	6	1.4	14	3.3
		20+	352	68	19.6	161	46.3	.	.	.	.	.	.	4	1.1	10	2.9
	<b>Age at diagnosis</b>	<1	3	.	.	1	33.3	.	.	.	.	.	.	.	.	.	.
		1-4	211	60	29.0	105	50.2	1	0.5	.	.	.	.	.	.	7	3.3
		5-9	404	97	24.2	208	51.9	.	.	.	.	.	.	2	0.5	6	1.5
		10-14	409	109	26.7	201	49.1	.	.	.	.	.	.	5	1.2	8	2.0
		15-20	263	49	18.8	148	57.1	2	0.8	.	.	3	1.2	7	2.7	22	8.5
<b>Females</b>	<b>All cases</b>		<b>625</b>	<b>178</b>	<b>28.8</b>	<b>338</b>	<b>54.6</b>	<b>1</b>	<b>0.2</b>	<b>.</b>	<b>.</b>	<b>1</b>	<b>0.2</b>	<b>5</b>	<b>0.8</b>	<b>28</b>	<b>4.5</b>
	<b>Age at baseline</b>	<18	62	26	41.9	28	45.2	1	1.6	.	.	.	.	.	.	2	3.2
		18-19	32	14	43.8	15	46.9	.	.	.	.	.	.	.	.	.	.
		20-24	141	40	28.6	80	57.1	.	.	.	.	.	.	1	0.7	3	2.1
		25-29	159	40	25.8	89	57.1	.	.	.	.	.	.	2	1.3	6	3.8
		30-34	152	44	28.9	80	52.6	.	.	.	.	1	0.7	1	0.7	8	5.3
		35+	79	14	18.2	46	59.7	.	.	.	.	.	.	1	1.3	9	11.8
	<b>Years since diagnosis</b>	5-9	33	11	33.3	16	48.5	.	.	.	.	.	.	1	3.0	3	9.1
		10-14	196	63	32.5	118	60.8	.	.	.	.	.	.	1	0.5	7	3.6
		15-19	231	61	26.8	125	54.8	1	0.4	.	.	1	0.4	2	0.9	6	2.6
		20+	165	43	26.4	79	48.2	.	.	.	.	.	.	1	0.6	12	7.3
	<b>Age at diagnosis</b>	<1	9	4	44.4	3	33.3	.	.	.	.	.	.	.	.	.	.
		1-4	104	40	38.8	50	48.5	1	1.0	.	.	.	.	.	.	.	.
		5-9	175	49	28.2	84	48.0	.	.	.	.	.	.	1	0.6	7	4.0
		10-14	193	56	29.5	108	56.8	.	.	.	.	1	0.5	1	0.5	8	4.2
		15-20	144	29	20.4	93	65.5	.	.	.	.	.	.	3	2.1	13	9.2

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values  
 Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years  
 If the starting date for a drug was not clearly prior to study entry, they are not included

			D Daunorubicin		D Doxorubicin		D Idarubicin		D Epirubicin		D Mitoxantrone		D Actinomycin-D		D Bleomycin		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
<b>Both sexes</b>	<b>All cases</b>		<b>2070</b>	<b>2</b>	<b>0.1</b>	<b>944</b>	<b>45.8</b>	.	.	.	.	<b>1</b>	<b>0.0</b>	<b>1952</b>	<b>94.9</b>	<b>2</b>	<b>0.1</b>
	<b>Age at baseline</b>	<18	761	.	.	374	49.1	.	.	.	.	.	.	721	94.9	1	0.1
		18-19	275	1	0.4	135	49.3	.	.	.	.	.	.	257	93.8	.	.
		20-24	611	1	0.2	264	43.5	.	.	.	.	.	.	574	94.6	1	0.2
		25-29	342	.	.	135	39.6	.	.	.	.	1	0.3	327	97.0	.	.
		30-34	66	.	.	30	46.2	.	.	.	.	.	.	60	92.3	.	.
		35+	15	.	.	6	40.0	.	.	.	.	.	.	13	92.9	.	.
	<b>Years since diagnosis</b>	5-9	167	.	.	89	53.3	.	.	.	.	.	.	161	96.4	.	.
		10-14	675	1	0.1	343	50.9	.	.	.	.	.	.	637	94.7	1	0.1
		15-19	679	1	0.1	320	47.4	.	.	.	.	.	.	633	93.8	1	0.1
		20+	549	.	.	192	35.1	.	.	.	.	1	0.2	521	96.1	.	.
	<b>Age at diagnosis</b>	<1	301	.	.	71	23.7	.	.	.	.	.	.	264	88.3	.	.
		1-4	1261	.	.	594	47.2	.	.	.	.	.	.	1211	96.5	2	0.2
		5-9	434	2	0.5	232	53.6	.	.	.	.	1	0.2	413	95.6	.	.
		10-14	54	.	.	36	69.2	.	.	.	.	.	.	46	90.2	.	.
		15-20	20	.	.	11	55.0	.	.	.	.	.	.	18	90.0	.	.
<b>Males</b>	<b>All cases</b>		<b>917</b>	.	.	<b>403</b>	<b>44.0</b>	.	.	.	.	<b>1</b>	<b>0.1</b>	<b>874</b>	<b>95.8</b>	<b>1</b>	<b>0.1</b>
	<b>Age at baseline</b>	<18	369	.	.	177	48.0	.	.	.	.	.	.	353	95.7	1	0.3
		18-19	111	.	.	49	44.1	.	.	.	.	.	.	103	92.8	.	.
		20-24	252	.	.	105	41.8	.	.	.	.	.	.	240	96.0	.	.
		25-29	152	.	.	56	36.8	.	.	.	.	1	0.7	145	97.3	.	.
		30-34	27	.	.	14	51.9	.	.	.	.	.	.	27	.	.	.
		35+	6	.	.	2	33.3	.	.	.	.	.	.	6	.	.	.
	<b>Years since diagnosis</b>	5-9	74	.	.	38	51.4	.	.	.	.	.	.	72	97.3	.	.
		10-14	307	.	.	148	48.2	.	.	.	.	.	.	294	95.8	1	0.3
		15-19	289	.	.	127	43.9	.	.	.	.	.	.	272	94.4	.	.
		20+	247	.	.	90	36.6	.	.	.	.	1	0.4	236	97.1	.	.
	<b>Age at diagnosis</b>	<1	149	.	.	35	23.6	.	.	.	.	.	.	131	88.5	.	.
		1-4	564	.	.	263	46.6	.	.	.	.	.	.	545	97.1	1	0.2
		5-9	177	.	.	87	49.2	.	.	.	.	1	0.6	172	97.7	.	.
		10-14	19	.	.	15	78.9	.	.	.	.	.	.	18	94.7	.	.
		15-20	8	.	.	3	37.5	.	.	.	.	.	.	8	.	.	.
<b>Females</b>	<b>All cases</b>		<b>1153</b>	<b>2</b>	<b>0.2</b>	<b>541</b>	<b>47.2</b>	.	.	.	.	.	.	<b>1078</b>	<b>94.1</b>	<b>1</b>	<b>0.1</b>
	<b>Age at baseline</b>	<18	392	.	.	197	50.3	.	.	.	.	.	.	368	94.1	.	.
		18-19	164	1	0.6	86	52.8	.	.	.	.	.	.	154	94.5	.	.
		20-24	359	1	0.3	159	44.7	.	.	.	.	.	.	334	93.6	1	0.3
		25-29	190	.	.	79	41.8	.	.	.	.	.	.	182	96.8	.	.
		30-34	39	.	.	16	42.1	.	.	.	.	.	.	33	86.8	.	.
		35+	9	.	.	4	44.4	.	.	.	.	.	.	7	87.5	.	.
	<b>Years since diagnosis</b>	5-9	93	.	.	51	54.8	.	.	.	.	.	.	89	95.7	.	.
		10-14	368	1	0.3	195	53.1	.	.	.	.	.	.	343	93.7	.	.
		15-19	390	1	0.3	193	50.0	.	.	.	.	.	.	361	93.3	1	0.3
		20+	302	.	.	102	33.9	.	.	.	.	.	.	285	95.3	.	.
	<b>Age at diagnosis</b>	<1	152	.	.	36	23.8	.	.	.	.	.	.	133	88.1	.	.
		1-4	697	.	.	331	47.6	.	.	.	.	.	.	666	96.0	1	0.1
		5-9	257	2	0.8	145	56.6	.	.	.	.	.	.	241	94.1	.	.
		10-14	35	.	.	21	63.6	.	.	.	.	.	.	28	87.5	.	.
		15-20	12	.	.	8	66.7	.	.	.	.	.	.	10	83.3	.	.

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values  
 Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years  
 If the starting date for a drug was not clearly prior to study entry, they are not included

			Daunorubicin		Doxorubicin		Idarubicin		Epirubicin		Mitoxantrone		Actinomycin-D		Bleomycin		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%		
<b>Both sexes</b>	<b>All cases</b>		<b>1798</b>	<b>10</b>	<b>0.6</b>	<b>743</b>	<b>41.8</b>	.	.	<b>1</b>	<b>0.1</b>	.	.	<b>19</b>	<b>1.1</b>	<b>2</b>	<b>0.1</b>
	<b>Age at baseline</b>	<18	889	4	0.5	407	46.1	.	.	.	.	.	.	8	0.9	2	0.2
		18-19	216	1	0.5	86	40.2	.	.	.	.	.	.	2	0.9	.	.
		20-24	504	3	0.6	194	38.8	.	.	1	0.2	.	.	2	0.4	.	.
		25-29	150	1	0.7	44	30.3	.	.	.	.	.	.	4	2.7	.	.
		30-34	34	1	3.1	10	31.3	.	.	.	.	.	.	3	9.4	.	.
		35+	5	.	.	2	40.0	.	.	.	.	.	.	.	.	.	.
	<b>Years since diagnosis</b>	5-9	152	2	1.3	89	59.3	.	.	.	.	.	.	2	1.3	.	.
		10-14	558	2	0.4	252	45.3	.	.	.	.	.	.	5	0.9	2	0.4
		15-19	594	2	0.3	241	41.1	.	.	1	0.2	.	.	4	0.7	.	.
		20+	494	4	0.8	161	33.2	.	.	.	.	.	.	8	1.6	.	.
	<b>Age at diagnosis</b>	<1	912	4	0.4	329	36.3	.	.	.	.	.	.	3	0.3	1	0.1
		1-4	706	5	0.7	332	47.6	.	.	1	0.1	.	.	9	1.3	1	0.1
		5-9	137	1	0.7	63	47.4	.	.	.	.	.	.	5	3.7	.	.
		10-14	27	.	.	11	42.3	.	.	.	.	.	.	2	7.7	.	.
		15-20	16	.	.	8	50.0	.	.	.	.	.	.	.	.	.	.
<b>Males</b>	<b>All cases</b>		<b>870</b>	<b>7</b>	<b>0.8</b>	<b>386</b>	<b>44.7</b>	.	.	.	.	.	.	<b>11</b>	<b>1.3</b>	<b>1</b>	<b>0.1</b>
	<b>Age at baseline</b>	<18	440	3	0.7	215	49.2	.	.	.	.	.	.	5	1.1	1	0.2
		18-19	94	1	1.1	43	45.7	.	.	.	.	.	.	1	1.1	.	.
		20-24	255	2	0.8	97	38.5	.	.	.	.	.	.	1	0.4	.	.
		25-29	65	.	.	24	37.5	.	.	.	.	.	.	2	3.1	.	.
		30-34	14	1	7.1	6	42.9	.	.	.	.	.	.	2	14.3	.	.
		35+	2	.	.	1	50.0	.	.	.	.	.	.	.	.	.	.
	<b>Years since diagnosis</b>	5-9	72	2	2.8	44	62.0	.	.	.	.	.	.	1	1.4	.	.
		10-14	274	1	0.4	132	48.2	.	.	.	.	.	.	3	1.1	1	0.4
		15-19	283	2	0.7	125	44.6	.	.	.	.	.	.	3	1.1	.	.
		20+	241	2	0.8	85	35.7	.	.	.	.	.	.	4	1.7	.	.
	<b>Age at diagnosis</b>	<1	470	3	0.6	177	37.8	.	.	.	.	.	.	2	0.4	1	0.2
		1-4	317	3	1.0	163	52.1	.	.	.	.	.	.	4	1.3	.	.
		5-9	67	1	1.5	37	56.1	.	.	.	.	.	.	4	6.1	.	.
		10-14	10	.	.	5	50.0	.	.	.	.	.	.	1	10.0	.	.
		15-20	6	.	.	4	66.7	.	.	.	.	.	.	.	.	.	.
<b>Females</b>	<b>All cases</b>		<b>928</b>	<b>3</b>	<b>0.3</b>	<b>357</b>	<b>39.0</b>	.	.	<b>1</b>	<b>0.1</b>	.	.	<b>8</b>	<b>0.9</b>	<b>1</b>	<b>0.1</b>
	<b>Age at baseline</b>	<18	449	1	0.2	192	43.1	.	.	.	.	.	.	3	0.7	1	0.2
		18-19	122	.	.	43	35.8	.	.	.	.	.	.	1	0.8	.	.
		20-24	249	1	0.4	97	39.1	.	.	1	0.4	.	.	1	0.4	.	.
		25-29	85	1	1.2	20	24.7	.	.	.	.	.	.	2	2.4	.	.
		30-34	20	.	.	4	22.2	.	.	.	.	.	.	1	5.6	.	.
		35+	3	.	.	1	33.3	.	.	.	.	.	.	.	.	.	.
	<b>Years since diagnosis</b>	5-9	80	.	.	45	57.0	.	.	.	.	.	.	1	1.3	.	.
		10-14	284	1	0.4	120	42.6	.	.	.	.	.	.	2	0.7	1	0.4
		15-19	311	.	.	116	37.8	.	.	1	0.3	.	.	1	0.3	.	.
		20+	253	2	0.8	76	30.8	.	.	.	.	.	.	4	1.6	.	.
	<b>Age at diagnosis</b>	<1	442	1	0.2	152	34.7	.	.	.	.	.	.	1	0.2	.	.
		1-4	389	2	0.5	169	44.0	.	.	1	0.3	.	.	5	1.3	1	0.3
		5-9	70	.	.	26	38.8	.	.	.	.	.	.	1	1.4	.	.
		10-14	17	.	.	6	37.5	.	.	.	.	.	.	1	6.3	.	.
		15-20	10	.	.	4	40.0	.	.	.	.	.	.	.	.	.	.

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values  
 Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years  
 If the starting date for a drug was not clearly prior to study entry, they are not included

			Daunorubicin		Doxorubicin		Idarubicin		Epirubicin		Mitoxantrone		Actinomycin-D		Bleomycin		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
<b>Both sexes</b>	<b>All cases</b>		<b>1588</b>	<b>5</b>	<b>0.3</b>	<b>641</b>	<b>40.7</b>	<b>.</b>	<b>.</b>	<b>1</b>	<b>0.1</b>	<b>1</b>	<b>0.1</b>	<b>1189</b>	<b>75.8</b>	<b>53</b>	<b>3.4</b>
	<b>Age at baseline</b>	<18	313	2	0.6	147	47.1	.	.	1	0.3	.	.	264	85.4	6	1.9
		18-19	115	.	.	43	37.7	.	.	.	.	.	.	99	86.8	4	3.5
		20-24	382	1	0.3	144	38.0	.	.	.	.	1	0.3	312	82.5	9	2.4
		25-29	351	2	0.6	145	41.9	.	.	.	.	.	.	263	75.8	12	3.4
		30-34	264	.	.	101	38.4	.	.	.	.	.	.	174	66.4	15	5.7
		35+	163	.	.	61	38.1	.	.	.	.	.	.	77	48.4	7	4.4
	<b>Years since diagnosis</b>	5-9	165	1	0.6	95	58.6	.	.	1	0.6	.	.	124	76.1	4	2.4
		10-14	473	3	0.6	197	41.9	.	.	.	.	1	0.2	351	75.0	20	4.2
		15-19	498	1	0.2	198	39.9	.	.	.	.	.	.	382	77.5	15	3.0
		20+	452	.	.	151	33.9	.	.	.	.	.	.	332	74.6	14	3.1
	<b>Age at diagnosis</b>	<1	108	.	.	29	27.1	.	.	1	0.9	.	.	79	73.8	2	1.9
		1-4	507	1	0.2	216	42.9	.	.	.	.	.	.	445	89.0	12	2.4
		5-9	361	2	0.6	128	35.6	.	.	.	.	1	0.3	304	84.7	6	1.7
		10-14	311	1	0.3	141	46.1	.	.	.	.	.	.	213	69.8	16	5.2
		15-20	301	1	0.3	127	42.8	.	.	.	.	.	.	148	49.7	17	5.7
<b>Males</b>	<b>All cases</b>		<b>847</b>	<b>3</b>	<b>0.4</b>	<b>343</b>	<b>40.8</b>	<b>.</b>	<b>.</b>	<b>.</b>	<b>.</b>	<b>.</b>	<b>.</b>	<b>653</b>	<b>77.9</b>	<b>30</b>	<b>3.6</b>
	<b>Age at baseline</b>	<18	179	1	0.6	90	50.3	.	.	.	.	.	.	156	88.1	2	1.1
		18-19	58	.	.	20	34.5	.	.	.	.	.	.	53	91.4	4	6.9
		20-24	213	1	0.5	76	36.0	.	.	.	.	.	.	169	80.5	4	1.9
		25-29	179	1	0.6	71	40.3	.	.	.	.	.	.	141	79.2	9	5.1
		30-34	139	.	.	52	37.7	.	.	.	.	.	.	94	68.6	8	5.8
		35+	79	.	.	34	43.6	.	.	.	.	.	.	40	51.3	3	3.8
	<b>Years since diagnosis</b>	5-9	89	1	1.1	55	63.2	.	.	.	.	.	.	71	80.7	.	.
		10-14	264	2	0.8	114	43.3	.	.	.	.	.	.	202	77.1	15	5.7
		15-19	252	.	.	95	38.0	.	.	.	.	.	.	198	79.8	9	3.6
		20+	242	.	.	79	32.9	.	.	.	.	.	.	182	75.8	6	2.5
	<b>Age at diagnosis</b>	<1	44	.	.	14	31.8	.	.	.	.	.	.	34	77.3	.	.
		1-4	293	.	.	125	42.8	.	.	.	.	.	.	260	90.0	8	2.7
		5-9	202	1	0.5	64	31.8	.	.	.	.	.	.	168	84.0	3	1.5
		10-14	167	1	0.6	79	48.2	.	.	.	.	.	.	115	70.1	12	7.3
		15-20	141	1	0.7	61	43.9	.	.	.	.	.	.	76	53.9	7	5.0
<b>Females</b>	<b>All cases</b>		<b>741</b>	<b>2</b>	<b>0.3</b>	<b>298</b>	<b>40.6</b>	<b>.</b>	<b>.</b>	<b>1</b>	<b>0.1</b>	<b>1</b>	<b>0.1</b>	<b>536</b>	<b>73.3</b>	<b>23</b>	<b>3.1</b>
	<b>Age at baseline</b>	<18	134	1	0.8	57	42.9	.	.	1	0.8	.	.	108	81.8	4	3.0
		18-19	57	.	.	23	41.1	.	.	.	.	.	.	46	82.1	.	.
		20-24	169	.	.	68	40.5	.	.	.	.	1	0.6	143	85.1	5	3.0
		25-29	172	1	0.6	74	43.5	.	.	.	.	.	.	122	72.2	3	1.8
		30-34	125	.	.	49	39.2	.	.	.	.	.	.	80	64.0	7	5.6
		35+	84	.	.	27	32.9	.	.	.	.	.	.	37	45.7	4	4.9
	<b>Years since diagnosis</b>	5-9	76	.	.	40	53.3	.	.	1	1.3	.	.	53	70.7	4	5.3
		10-14	209	1	0.5	83	40.1	.	.	.	.	1	0.5	149	72.3	5	2.4
		15-19	246	1	0.4	103	41.9	.	.	.	.	.	.	184	75.1	6	2.4
		20+	210	.	.	72	35.0	.	.	.	.	.	.	150	73.2	8	3.9
	<b>Age at diagnosis</b>	<1	64	.	.	15	23.8	.	.	1	1.6	.	.	45	71.4	2	3.2
		1-4	214	1	0.5	91	42.9	.	.	.	.	.	.	185	87.7	4	1.9
		5-9	159	1	0.6	64	40.3	.	.	.	.	1	0.6	136	85.5	3	1.9
		10-14	144	.	.	62	43.7	.	.	.	.	.	.	98	69.5	4	2.8
		15-20	160	.	.	66	41.8	.	.	.	.	.	.	72	45.9	10	6.3

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values  
 Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years  
 If the starting date for a drug was not clearly prior to study entry, they are not included

			Daunorubicin		Doxorubicin		Idarubicin		Epirubicin		Mitoxantrone		Actinomycin-D		Bleomycin		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
<b>Both sexes</b>	<b>All cases</b>		<b>1931</b>	<b>5</b>	<b>0.3</b>	<b>1672</b>	<b>87.7</b>	<b>.</b>	<b>.</b>	<b>1</b>	<b>0.1</b>	<b>.</b>	<b>.</b>	<b>761</b>	<b>39.7</b>	<b>338</b>	<b>17.6</b>
	<b>Age at baseline</b>	<18	85	.	.	82	97.6	.	.	.	.	.	.	37	44.0	11	12.9
		18-19	66	.	.	58	87.9	.	.	.	.	.	.	39	59.1	14	21.2
		20-24	359	.	.	336	94.1	.	.	1	0.3	.	.	182	50.8	88	24.6
		25-29	528	2	0.4	465	89.6	.	.	.	.	.	.	200	38.2	81	15.5
		30-34	517	.	.	439	86.1	.	.	.	.	.	.	172	33.4	75	14.6
		35+	376	3	0.8	292	78.7	.	.	.	.	.	.	131	35.3	69	18.5
	<b>Years since diagnosis</b>	5-9	214	.	.	198	93.0	.	.	1	0.5	.	.	122	57.3	68	31.9
		10-14	629	1	0.2	560	90.3	.	.	.	.	.	.	238	38.1	125	20.0
		15-19	633	1	0.2	562	89.8	.	.	.	.	.	.	227	36.1	73	11.6
		20+	455	3	0.7	352	78.6	.	.	.	.	.	.	174	38.5	72	15.9
	<b>Age at diagnosis</b>	<1	8	.	.	6	75.0	.	.	.	.	.	.	3	37.5	.	.
		1-4	80	.	.	71	91.0	.	.	.	.	.	.	40	50.6	8	10.0
		5-9	338	1	0.3	306	90.8	.	.	.	.	.	.	143	42.3	35	10.4
		10-14	774	2	0.3	678	88.9	.	.	1	0.1	.	.	317	41.3	151	19.7
		15-20	731	2	0.3	611	84.7	.	.	.	.	.	.	258	35.6	144	19.8
<b>Males</b>	<b>All cases</b>		<b>978</b>	<b>3</b>	<b>0.3</b>	<b>865</b>	<b>89.4</b>	<b>.</b>	<b>.</b>	<b>1</b>	<b>0.1</b>	<b>.</b>	<b>.</b>	<b>404</b>	<b>41.6</b>	<b>170</b>	<b>17.5</b>
	<b>Age at baseline</b>	<18	43	.	.	42	97.7	.	.	.	.	.	.	22	51.2	7	16.3
		18-19	33	.	.	28	84.8	.	.	.	.	.	.	22	66.7	5	15.2
		20-24	174	.	.	163	94.2	.	.	1	0.6	.	.	92	53.2	37	21.4
		25-29	274	2	0.7	245	90.7	.	.	.	.	.	.	100	36.8	41	15.1
		30-34	255	.	.	226	89.7	.	.	.	.	.	.	98	38.6	43	16.9
		35+	199	1	0.5	161	81.7	.	.	.	.	.	.	70	35.5	37	18.7
	<b>Years since diagnosis</b>	5-9	114	.	.	105	92.9	.	.	1	0.9	.	.	66	58.4	32	28.3
		10-14	318	1	0.3	287	91.4	.	.	.	.	.	.	130	41.1	65	20.6
		15-19	320	1	0.3	293	92.1	.	.	.	.	.	.	115	36.2	37	11.6
		20+	226	1	0.4	180	80.7	.	.	.	.	.	.	93	41.3	36	16.0
	<b>Age at diagnosis</b>	<1	4	.	.	3	75.0	.	.	.	.	.	.	2	50.0	.	.
		1-4	41	.	.	37	90.2	.	.	.	.	.	.	25	61.0	4	9.8
		5-9	173	1	0.6	155	90.1	.	.	.	.	.	.	80	46.2	19	11.0
		10-14	362	.	.	325	90.8	.	.	1	0.3	.	.	157	43.7	63	17.5
		15-20	398	2	0.5	345	87.8	.	.	.	.	.	.	140	35.4	84	21.2
<b>Females</b>	<b>All cases</b>		<b>953</b>	<b>2</b>	<b>0.2</b>	<b>807</b>	<b>85.9</b>	<b>.</b>	<b>.</b>	<b>.</b>	<b>.</b>	<b>.</b>	<b>.</b>	<b>357</b>	<b>37.7</b>	<b>168</b>	<b>17.7</b>
	<b>Age at baseline</b>	<18	42	.	.	40	97.6	.	.	.	.	.	.	15	36.6	4	9.5
		18-19	33	.	.	30	90.9	.	.	.	.	.	.	17	51.5	9	27.3
		20-24	185	.	.	173	94.0	.	.	.	.	.	.	90	48.6	51	27.6
		25-29	254	.	.	220	88.4	.	.	.	.	.	.	100	39.7	40	15.9
		30-34	262	.	.	213	82.6	.	.	.	.	.	.	74	28.4	32	12.3
		35+	177	2	1.1	131	75.3	.	.	.	.	.	.	61	35.1	32	18.4
	<b>Years since diagnosis</b>	5-9	100	.	.	93	93.0	.	.	.	.	.	.	56	56.0	36	36.0
		10-14	311	.	.	273	89.2	.	.	.	.	.	.	108	35.1	60	19.4
		15-19	313	.	.	269	87.3	.	.	.	.	.	.	112	36.0	36	11.6
		20+	229	2	0.9	172	76.4	.	.	.	.	.	.	81	35.7	36	15.9
	<b>Age at diagnosis</b>	<1	4	.	.	3	75.0	.	.	.	.	.	.	1	25.0	.	.
		1-4	39	.	.	34	91.9	.	.	.	.	.	.	15	39.5	4	10.3
		5-9	165	.	.	151	91.5	.	.	.	.	.	.	63	38.2	16	9.7
		10-14	412	2	0.5	353	87.2	.	.	.	.	.	.	160	39.1	88	21.5
		15-20	333	.	.	266	81.1	.	.	.	.	.	.	118	35.8	60	18.2

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values  
 Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years  
 If the starting date for a drug was not clearly prior to study entry, they are not included

		All cases		D Daunorubicin		D Doxorubicin		I Idarubicin		E Epirubicin		M Mitoxantrone		A Actinomycin-D		B Bleomycin	
		All cases		N	%	N	%	N	%	N	%	N	%	N	%	N	%
<b>Both sexes</b>	<b>All cases</b>	<b>685</b>		<b>1</b>	<b>0.1</b>	<b>613</b>	<b>90.8</b>	.	.	.	.	.	.	<b>426</b>	<b>62.6</b>	<b>29</b>	<b>4.2</b>
	<b>Age at baseline</b>	<18	54	.	.	52	98.1	.	.	.	.	.	.	26	49.1	.	.
		18-19	33	.	.	30	90.9	.	.	.	.	.	.	24	72.7	2	6.1
		20-24	157	.	.	149	96.1	.	.	.	.	.	.	91	58.3	5	3.2
		25-29	193	1	0.5	175	91.6	.	.	.	.	.	.	120	62.2	6	3.1
		30-34	153	.	.	128	85.9	.	.	.	.	.	.	98	64.5	5	3.3
		35+	95	.	.	79	84.0	.	.	.	.	.	.	67	71.3	11	11.6
	<b>Years since diagnosis</b>	5-9	90	.	.	83	93.3	.	.	.	.	.	.	52	58.4	3	3.4
		10-14	231	.	.	223	97.4	.	.	.	.	.	.	119	51.7	7	3.0
		15-19	214	1	0.5	192	91.9	.	.	.	.	.	.	150	70.8	9	4.2
		20+	150	.	.	115	77.7	.	.	.	.	.	.	105	70.0	10	6.7
	<b>Age at diagnosis</b>	<1	4	.	.	3	75.0	.	.	.	.	.	.	2	50.0	.	.
		1-4	50	.	.	44	91.7	.	.	.	.	.	.	30	61.2	1	2.0
		5-9	170	1	0.6	157	92.4	.	.	.	.	.	.	106	62.4	4	2.4
		10-14	257	.	.	221	87.7	.	.	.	.	.	.	164	64.1	9	3.5
		15-20	204	.	.	188	93.5	.	.	.	.	.	.	124	61.4	15	7.4
<b>Males</b>	<b>All cases</b>	<b>353</b>		<b>1</b>	<b>0.3</b>	<b>325</b>	<b>92.9</b>	.	.	.	.	.	.	<b>235</b>	<b>67.0</b>	<b>14</b>	<b>4.0</b>
	<b>Age at baseline</b>	<18	24	.	.	23	95.8	.	.	.	.	.	.	15	62.5	.	.
		18-19	17	.	.	15	88.2	.	.	.	.	.	.	16	94.1	1	5.9
		20-24	78	.	.	76	98.7	.	.	.	.	.	.	52	67.5	2	2.6
		25-29	99	1	1.0	92	92.9	.	.	.	.	.	.	60	60.6	2	2.0
		30-34	83	.	.	76	92.7	.	.	.	.	.	.	57	68.7	4	4.8
		35+	52	.	.	43	84.3	.	.	.	.	.	.	35	68.6	5	9.6
	<b>Years since diagnosis</b>	5-9	48	.	.	45	95.7	.	.	.	.	.	.	33	70.2	1	2.1
		10-14	109	.	.	106	97.2	.	.	.	.	.	.	66	60.6	2	1.8
		15-19	115	1	0.9	110	96.5	.	.	.	.	.	.	77	67.5	5	4.3
		20+	81	.	.	64	80.0	.	.	.	.	.	.	59	72.8	6	7.4
	<b>Age at diagnosis</b>	<1	2	.	.	1	50.0	.	.	.	.	.	.	1	50.0	.	.
		1-4	26	.	.	24	92.3	.	.	.	.	.	.	20	76.9	1	3.8
		5-9	84	1	1.2	78	92.9	.	.	.	.	.	.	59	70.2	3	3.6
		10-14	135	.	.	121	91.0	.	.	.	.	.	.	95	70.9	4	3.0
		15-20	106	.	.	101	96.2	.	.	.	.	.	.	60	57.1	6	5.7
<b>Females</b>	<b>All cases</b>	<b>332</b>		.	.	<b>288</b>	<b>88.6</b>	.	.	.	.	.	.	<b>191</b>	<b>57.9</b>	<b>15</b>	<b>4.5</b>
	<b>Age at baseline</b>	<18	30	.	.	29	.	.	.	.	.	.	.	11	37.9	.	.
		18-19	16	.	.	15	93.8	.	.	.	.	.	.	8	50.0	1	6.3
		20-24	79	.	.	73	93.6	.	.	.	.	.	.	39	49.4	3	3.8
		25-29	94	.	.	83	90.2	.	.	.	.	.	.	60	63.8	4	4.3
		30-34	70	.	.	52	77.6	.	.	.	.	.	.	41	59.4	1	1.4
		35+	43	.	.	36	83.7	.	.	.	.	.	.	32	74.4	6	14.0
	<b>Years since diagnosis</b>	5-9	42	.	.	38	90.5	.	.	.	.	.	.	19	45.2	2	4.8
		10-14	122	.	.	117	97.5	.	.	.	.	.	.	53	43.8	5	4.1
		15-19	99	.	.	82	86.3	.	.	.	.	.	.	73	74.5	4	4.1
		20+	69	.	.	51	75.0	.	.	.	.	.	.	46	66.7	4	5.8
	<b>Age at diagnosis</b>	<1	2	.	.	2	.	.	.	.	.	.	.	1	50.0	.	.
		1-4	24	.	.	20	90.9	.	.	.	.	.	.	10	43.5	.	.
		5-9	86	.	.	79	91.9	.	.	.	.	.	.	47	54.7	1	1.2
		10-14	122	.	.	100	84.0	.	.	.	.	.	.	69	56.6	5	4.1
		15-20	98	.	.	87	90.6	.	.	.	.	.	.	64	66.0	9	9.3

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values  
 Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years  
 If the starting date for a drug was not clearly prior to study entry, they are not included

			Daunorubicin		Doxorubicin		Idarubicin		Epirubicin		Mitoxantrone		Actinomycin-D		Bleomycin		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%
<b>Both sexes</b>	<b>All cases</b>		<b>1149</b>	<b>4</b>	<b>0.3</b>	<b>1004</b>	<b>88.5</b>	<b>.</b>	<b>.</b>	<b>1</b>	<b>0.1</b>	<b>.</b>	<b>.</b>	<b>308</b>	<b>27.0</b>	<b>308</b>	<b>27.0</b>
	<b>Age at baseline</b>	<18	25	.	.	25	.	.	.	.	.	.	.	11	44.0	11	44.0
		18-19	27	.	.	24	88.9	.	.	.	.	.	.	12	44.4	12	44.4
		20-24	183	.	.	172	94.0	.	.	1	0.5	.	.	84	45.9	82	44.8
		25-29	317	1	0.3	279	90.0	.	.	.	.	.	.	73	23.3	75	24.0
		30-34	337	.	.	297	88.9	.	.	.	.	.	.	69	20.5	70	20.8
		35+	260	3	1.2	207	80.9	.	.	.	.	.	.	59	23.0	58	22.7
	<b>Years since diagnosis</b>	5-9	118	.	.	111	94.1	.	.	1	0.8	.	.	67	56.8	65	55.1
		10-14	361	1	0.3	313	88.4	.	.	.	.	.	.	113	31.7	117	32.8
		15-19	390	.	.	353	91.0	.	.	.	.	.	.	69	17.8	64	16.5
		20+	280	3	1.1	227	82.5	.	.	.	.	.	.	59	21.3	62	22.4
	<b>Age at diagnosis</b>	1-4	21	.	.	20	95.2	.	.	.	.	.	.	7	33.3	7	33.3
		5-9	151	.	.	140	93.3	.	.	.	.	.	.	33	21.9	31	20.5
		10-14	491	2	0.4	437	90.1	.	.	1	0.2	.	.	139	28.6	141	29.0
		15-20	486	2	0.4	407	85.0	.	.	.	.	.	.	129	26.8	129	26.8
<b>Males</b>	<b>All cases</b>		<b>577</b>	<b>2</b>	<b>0.3</b>	<b>514</b>	<b>90.2</b>	<b>.</b>	<b>.</b>	<b>1</b>	<b>0.2</b>	<b>.</b>	<b>.</b>	<b>156</b>	<b>27.2</b>	<b>156</b>	<b>27.2</b>
	<b>Age at baseline</b>	<18	18	.	.	18	.	.	.	.	.	.	.	7	38.9	7	38.9
		18-19	12	.	.	11	91.7	.	.	.	.	.	.	4	33.3	4	33.3
		20-24	86	.	.	79	91.9	.	.	1	1.2	.	.	36	41.9	35	40.7
		25-29	165	1	0.6	148	91.9	.	.	.	.	.	.	37	22.7	39	23.9
		30-34	158	.	.	143	91.7	.	.	.	.	.	.	39	24.8	39	24.8
		35+	138	1	0.7	115	83.9	.	.	.	.	.	.	33	24.1	32	23.4
	<b>Years since diagnosis</b>	5-9	64	.	.	59	92.2	.	.	1	1.6	.	.	32	50.0	31	48.4
		10-14	190	1	0.5	168	90.3	.	.	.	.	.	.	60	31.9	63	33.5
		15-19	190	.	.	176	93.1	.	.	.	.	.	.	35	18.5	32	16.9
		20+	133	1	0.8	111	84.7	.	.	.	.	.	.	29	22.0	30	22.7
	<b>Age at diagnosis</b>	1-4	11	.	.	11	.	.	.	.	.	.	.	3	27.3	3	27.3
		5-9	76	.	.	70	93.3	.	.	.	.	.	.	17	22.4	16	21.1
		10-14	220	.	.	199	91.3	.	.	1	0.5	.	.	59	27.1	59	27.1
		15-20	270	2	0.7	234	88.0	.	.	.	.	.	.	77	28.7	78	29.1
<b>Females</b>	<b>All cases</b>		<b>572</b>	<b>2</b>	<b>0.4</b>	<b>490</b>	<b>86.7</b>	<b>.</b>	<b>.</b>	<b>.</b>	<b>.</b>	<b>.</b>	<b>.</b>	<b>152</b>	<b>26.8</b>	<b>152</b>	<b>26.8</b>
	<b>Age at baseline</b>	<18	7	.	.	7	.	.	.	.	.	.	.	4	57.1	4	57.1
		18-19	15	.	.	13	86.7	.	.	.	.	.	.	8	53.3	8	53.3
		20-24	97	.	.	93	95.9	.	.	.	.	.	.	48	49.5	47	48.5
		25-29	152	.	.	131	87.9	.	.	.	.	.	.	36	24.0	36	24.0
		30-34	179	.	.	154	86.5	.	.	.	.	.	.	30	16.8	31	17.3
		35+	122	2	1.7	92	77.3	.	.	.	.	.	.	26	21.8	26	21.8
	<b>Years since diagnosis</b>	5-9	54	.	.	52	96.3	.	.	.	.	.	.	35	64.8	34	63.0
		10-14	171	.	.	145	86.3	.	.	.	.	.	.	53	31.4	54	32.0
		15-19	200	.	.	177	88.9	.	.	.	.	.	.	34	17.1	32	16.1
		20+	147	2	1.4	116	80.6	.	.	.	.	.	.	30	20.7	32	22.1
	<b>Age at diagnosis</b>	1-4	10	.	.	9	90.0	.	.	.	.	.	.	4	40.0	4	40.0
		5-9	75	.	.	70	93.3	.	.	.	.	.	.	16	21.3	15	20.0
		10-14	271	2	0.7	238	89.1	.	.	.	.	.	.	80	29.9	82	30.6
		15-20	216	.	.	173	81.2	.	.	.	.	.	.	52	24.3	51	23.8

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values  
 Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years  
 If the starting date for a drug was not clearly prior to study entry, they are not included